olverembatinib
ascentage pharmaceuticals
['olverembatinib']
dcbn news: live from asco 2023 | updated data of olverembatinib in sdh-deficient gist including a cbr of 93.8% signals a potential clinical breakthrough: suzhou, china and rockville, md., june 4, 2023 ... #biotech #news 
Life science news and jobs from Washington DC, Maryland and Virginia. Part of @BiotechNetworks, connecting #biotech since 2008.